Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with TACE for advanced hepatocellular carcinoma
ChiCTR1900026163Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC) and liver cancer, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: progression-free survival. Started Oct 2019; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR1900026163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026163.